# A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised Adults

> **NCT05366322** · — · COMPLETED · sponsor: **ModernaTX, Inc.** · enrollment: 124879 (actual)

## Conditions studied

- SARS-CoV-2

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05366322
- **Lead sponsor:** ModernaTX, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-10
- **Primary completion:** 2022-02-04
- **Final completion:** 2022-03-21
- **Target enrollment:** 124879 (ACTUAL)
- **Last updated:** 2022-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05366322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05366322, "A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised Adults". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05366322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*